Lord, Abbett & Co
AMRI

Lord, Abbett & Co’s Albany Molecular Research Inc AMRI Stock Holding History

Lord, Abbett & Co’s Portfolio AMRI Stock Details AMRI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-693,107
Closed -$9.72M – 970
2017
Q1 		$9.72M Buy
+693,107
New +$11.4M 0.03% 609

Other funds holding AMRI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
American Capital Management New York $1.86B AUM 20.23% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CCM
Chicago Capital Management Chicago, Illinois $121M AUM 74.36% 1-Year Est. Return
EWM
Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return

Lord, Abbett & Co's AMRI Position: Q2 2017 in Review

Lord, Abbett & Co sold out of Albany Molecular Research Inc (AMRI) in Q2 2017, closing a stake of 693,107 shares — an estimated $9.72M sold.

Lord, Abbett & Co first reported a position in AMRI in Q1 2017 and held it in 1 quarter. The position peaked at $9.72M in Q1 2017. 136 funds tracked by Wall St. Rank hold AMRI as of Q2 2017.

  • Lord, Abbett & Co reported no remaining Albany Molecular Research Inc position as of Q2 2017 after selling out during the quarter.
  • Lord, Abbett & Co sold 693,107 Albany Molecular Research Inc shares in Q2 2017, an estimated $9.72M.
  • Lord, Abbett & Co first reported a position in Albany Molecular Research Inc in Q1 2017 and held it in 1 quarter.
  • Lord, Abbett & Co's Albany Molecular Research Inc position peaked at $9.72M in Q1 2017.
  • 136 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q2 2017.

Based on Lord, Abbett & Co's 13F filing for Q2 2017, filed 14 Aug 2017.